Moleculin Biotech Inc Dossier
Qualitative Analysis
Business overview
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company focused on developing a pipeline of oncology drug candidates to treat highly resistant tumors and viruses. The company's lead clinical program is Annamycin (naxtarubicin), a next-generation liposomal anthracycline designed to bypass multidrug resistance mechanisms and eliminate the cardiotoxicity typical of conventional anthracyclines. Annamycin is currently being evaluated in the pivotal, adaptive-design Phase 3 MIRACLE trial in combination with cytarabine (referred to as AnnAraC) for adult patients with relapsed or refractory acute myeloid leukemia (AML). Beyond Annamycin, Moleculin's pipeline includes WP1066, an immune/transcription modulator targeting p-STAT3 in brain tumors and other cancers, and WP1122, an antimetabolite portfolio candidate targeting viral infections and specific cancer indications.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the registration-directed MIRACLE trial evaluating AnnAraC (Annamycin combined with Ara-C) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in Europe.
Expected impact: Aims to demonstrate superior efficacy and lack of cardiotoxicity compared to standard anthracyclines, supporting a streamlined pathway toward accelerated FDA approval.
Expanding the clinical development of Annamycin into solid tumor indications, specifically targeting pancreatic cancer and glioblastoma multiforme (GBM) through investigator-initiated and grant-funded collaborations.
Expected impact: Establishes Annamycin as a versatile 'pipeline in a product' by demonstrating therapeutic activity beyond hematological malignancies.
Engaging industry experts and advisors to actively explore strategic partnerships, licensing agreements, and non-dilutive funding options to optimize the commercial value of Annamycin and extend financial runway.
Expected impact: Aims to secure global or regional development and commercialization partners, mitigating clinical execution risks and funding requirements.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Atlantic Health will fund and conduct a Phase 1B/2 single-arm study evaluating Annamycin for the third-line treatment of advanced pancreatic cancer [2.1.5]. This institutional backing provides independent validation of Annamycin's potential in solid tumors.
Terms: Atlantic Health is responsible for conducting and funding the study; Moleculin expects to incur approximately $1 million in costs primarily for drug supply and external laboratory testing through 2030.
Focuses on evaluating the tumor progression and efficacy of intra-arterial delivery of liposomal Annamycin (L-Annamycin) and Free-Annamycin in preclinical mouse models of glioblastoma multiforme (GBM).
Terms: Moleculin supplies Annamycin, while CIC biomaGUNE conducts and oversees the preclinical research.
A grant-funded preclinical research collaboration to evaluate the therapeutic potential of Annamycin in pancreatic cancer models.
Terms: Grant-funded; specific financial terms were not disclosed.